Association of Lipoprotein‐Associated Phospholipase A2 and Lipoprotein(a) With the Risk of Recurrence Stroke in Patients With Acute Ischemic Stroke

Yu Feng,Shenyang Zhang,Hailiang Li,Hao Li,Ruiguo Dong,Shiguang Zhu,Yanlong Zhou
DOI: https://doi.org/10.1002/jcla.25120
IF: 3.124
2024-12-05
Journal of Clinical Laboratory Analysis
Abstract:Lipoprotein‐associated phospholipase A2 and lipoprotein(a) can be used to predict major adverse cerebrovascular events in patients with acute ischemic stroke. The combined impact of Lp‐PLA2 in conjunction with Lp(a) as a more precise and cost‐effective predictive tool for the risk of recurrence stroke in patients with AIS. Lp‐PLA2 and Lp(a) are independently associated with major adverse cerebrovascular events in patients with acute ischemic stroke. Lp‐PLA2 and Lp(a) were simple and easy to obtain and can be considered as a routine test. Objective It is still a major global challenge to reduce the high morbidity and mortality of acute ischemic stroke (AIS) and improve the prognosis of patients. This study aims to investigate the prognostic value of lipoprotein‐associated phospholipase A2 (Lp‐PLA2) combined with lipoprotein(a) (Lp(a)) for long‐term stroke recurrence in patients with AIS. Methods This study included 580 patients with AIS. Assessment of Lp‐PLA2 and Lp(a) levels was conducted upon patient admission. Continuous monitoring over the long term categorized stroke recurrence as an endpoint. Patients were categorized based on these identified thresholds to compare the risk of stroke recurrence: high Lp‐PLA2 and high Lp(a), high Lp‐PLA2 and low Lp(a), low Lp‐PLA2 and high Lp(a), and low Lp‐PLA2 combined with low Lp(a). Results Among the 580 participants, 101 individuals (17.41%) experienced stroke recurrence within the 2‐year follow‐up. The majority were male (61.39%), with a median age of 62 years (interquartile range: 55–69.5). Factors independently associated with heightened the risk of recurrence stroke comprised age (hazard ratio [HR], 1.025; p = 0.021), diabetes mellitus (HR, 1.751; p = 0.007), Lp‐PLA2 (HR, 1.004; p
medical laboratory technology
What problem does this paper attempt to address?